Efficacy and Safety of Lumiracoxib 400 mg in Arthroscopic Knee Surgery

Novartis

Status and phase

Completed

Phase 4

Conditions

Pain

Treatments

Drug: Lumiracoxib

Study type

Interventional

Funder types

Industry

Identifiers

NCT00333567

CCOX189A2427

Details and patient eligibility

About

This study is designed to investigate the efficacy and safety of a single daily dose of 400 mg lumiracoxib given pre-emptively versus post-operatively in terms of efficacy in reducing pain associated with ambulatory arthroscopic knee surgery

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients who need scheduled minor ambulatory arthroscopic knee surgery.

Exclusion criteria

Patients with any surgical or medical conditions which could place the patient at higher risk from his/her participation in the study, or are likely to prevent the patient from complying with the requirements of the study or completing the trial period.

Other protocol-defined inclusion/exclusion criteria may apply.